Myeloproliferative Dz News http://www.mdlinx.com/oncology/news.cfm/newspage/1/spec_id/17/subspec_id/388 Myeloproliferative Dz en-us Copyright 2013 MDLinx, Inc. <![CDATA[Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes]]> http://www.mdlinx.com/oncology/news-article.cfm/4638630/?xml 5/24/2013 Clinical Cancer Research]]> http://www.mdlinx.com/oncology/news-article.cfm/4638630/?xml <![CDATA[Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction]]> http://www.mdlinx.com/oncology/news-article.cfm/4618157/?xml 5/24/2013 Hematology]]> http://www.mdlinx.com/oncology/news-article.cfm/4618157/?xml <![CDATA[GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells]]> http://www.mdlinx.com/oncology/news-article.cfm/4639450/?xml 5/24/2013 Hematology]]> http://www.mdlinx.com/oncology/news-article.cfm/4639450/?xml